D-9-Tetrahydrocannabiphorol (THCP)

In December 2019, a team of Italian researchers published a paper in Scientific Reports that changed how scientists think about cannabis potency. They had discovered a naturally occurring phytocannabinoid with a seven-carbon side chain — two carbons longer than standard Δ9-THC’s five — and it bound to CB1 receptors with 33 times greater affinity than Δ9-THC in laboratory assays. The compound: delta-9-tetrahydrocannabiphorol (THCP) (Citti et al., 2019).

The discovery immediately triggered both scientific interest and significant consumer hype. Understanding what THCP actually is — and what the “33x stronger” claim does and doesn’t mean — is the purpose of this guide.

What Is THCP?

THCP (Δ9-tetrahydrocannabiphorol) is a naturally occurring phytocannabinoid in Cannabis sativa L. It is a homolog of Δ9-THC in which the standard pentyl (five-carbon) alkyl side chain at the resorcinol ring position is extended to a heptyl (seven-carbon) chain. This two-carbon extension is sufficient to dramatically increase the compound’s fit within the CB1 receptor binding pocket (Citti et al., 2019; Wikipedia contributors, 2025).

THCP was discovered by the same Italian research group (University of Modena and Reggio Emilia) that had previously isolated THC-C4/THCB. They found THCP while conducting detailed mass spectrometry profiling of the FM2 Italian medical cannabis strain. Its natural concentration in cannabis is very low — trace level — meaning it is not a practically significant source of cannabis’s psychoactive effects through normal plant consumption (Citti et al., 2019).

The 2019 Discovery

The Citti et al. (2019) paper — “A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol” — was published in Scientific Reports (Nature portfolio). The team isolated THCP from FM2 cannabis, confirmed its structure by stereoselective synthesis and comprehensive spectroscopic methods, and then characterized its pharmacology.

Their key findings: THCP demonstrated CB1 receptor affinity with a Ki of 1.2 nM compared to Δ9-THC’s ~40 nM — approximately a 33-fold difference. In vivo tetrad testing in mice (the standard behavioral assay for CB1 agonism) showed THCP produced “full agonist behavior” at the same 10 mg/kg dose used for Δ9-THC, with cannabimimetic activity described as “far higher” (Citti et al., 2019; ScienceDirect, 2024).

What “33× Greater Binding Affinity” Actually Means

The “33x stronger” figure that dominates THCP marketing requires careful interpretation. The Ki value (1.2 nM vs ~40 nM for Δ9-THC) measures how strongly the compound binds to isolated CB1 receptors in a laboratory assay — not how intense the effect is in a living person. Several factors separate binding affinity from real-world potency:

Binding affinity describes how tightly the molecule fits the receptor. But receptor activation efficiency (efficacy), bioavailability (how much reaches the brain), metabolism rate, and tolerance all determine what someone actually experiences. THCP’s natural concentration in cannabis is trace-level — unlikely to contribute meaningfully to the effects of normal cannabis use. And user reports suggest THCP effects are roughly 5–10× more intense than Δ9-THC in practice — significant, but far below the 33× binding number (Wikipedia contributors, 2025; Canapuff, 2025).

Frequently Asked Questions

The Bottom Line

THCP’s discovery in 2019 was a genuine scientific milestone — the first naturally occurring cannabinoid with CB1 binding affinity substantially exceeding that of Δ9-THC, and an important finding for understanding the full pharmacological potential of the cannabis plant. It also raised important questions about cannabis potency: if trace amounts of THCP exist in some strains, they may contribute to the variability in effects that isn’t fully explained by Δ9-THC content alone.

For consumers, THCP products require substantially more caution than standard THC products given their greater potency. The “33× stronger” headline is technically about receptor binding, not subjective experience — but even a practical 5–10× potency multiplier represents a meaningfully higher-risk pharmacological profile than standard cannabis.

Nothing in this article constitutes medical advice. Always consult a qualified healthcare provider before making any decisions about supplementation or treatment.

Back to List of Cannabinoids